The government’s pitch for genomic medicine is genuinely compelling. Sequence your DNA, understand your disease risk, target your cancer treatment precisely, and spare you years of misdiagnosis. The NHS Genomic Medicine Service (GMS), launched in 2018 and formally expanded through the 2020s, is supposed to be the engine that delivers that future to every patient in England. On paper, the UK leads the world. In practice, the picture is considerably messier, and I think most patients would be surprised by how far day-to-day clinical reality lags behind the announcements.
This is not a story about failure. The science is real, the ambition is right, and there are places where genomic medicine is genuinely changing lives today. But the gap between government rhetoric and what most patients actually encounter is wide enough to deserve honest examination, and that gap has consequences.
What the NHS Genomic Medicine Service actually is
The GMS operates through seven Genomic Laboratory Hubs across England, each covering a large geographic region. These hubs process genetic tests ordered by clinicians, link into a shared NHS Genomic Medicine Service dataset, and are meant to be the infrastructure through which whole genome sequencing eventually becomes routine. Genomics England, a company owned by the Department of Health, runs the 100,000 Genomes Project data and feeds into this infrastructure. Together, these bodies represent a genuinely significant investment: the government has committed hundreds of millions of pounds to the programme since its inception.
The GMS focuses primarily on rare diseases and cancer genomics. For a child with an undiagnosed rare condition, a whole genome sequence can end a diagnostic odyssey that might otherwise take a decade. For a patient with certain cancers, tumour profiling can identify whether a targeted therapy will work before expensive and gruelling treatment begins. These are real, meaningful applications, not theoretical ones. According to Genomics England, whole genome sequencing has now provided a diagnosis for around 25 per cent of previously undiagnosed rare disease patients who go through the programme. That is not nothing. For those families, it is everything.
Where the access gaps are widest
The problem starts with referral. A whole genome sequence only helps if a clinician thinks to order one, knows how to interpret the result, and has access to a genetics specialist who can act on it. Across much of England, particularly in rural areas and in the Midlands and North, that chain is broken at multiple points.
The NHS has around 3,500 registered clinical geneticists and genetic counsellors in total, according to NHS workforce figures. For a population of 56 million in England alone, that number is inadequate. Most GPs have had minimal genomics training. A 2023 Health Education England review found that fewer than a third of NHS trusts felt their non-specialist clinicians had sufficient understanding to order or act on genomic tests appropriately. That figure has not materially improved since. What this means in practice is that access to NHS genomic medicine in the UK often depends on whether you happen to be treated by a clinician who knows enough to refer you, or who works somewhere with a strong genetics team nearby.
Geography compounds the problem. The seven Genomic Laboratory Hubs are not evenly spread. Patients in London or Manchester are significantly better served by specialist genetics outpatient services than patients in Cornwall, Lincolnshire or large parts of Wales, where the NHS in Wales has its own separate genomics programme that lacks equivalent infrastructure investment. Health inequality, which runs through almost every part of the NHS, runs through genomics too.
Ethnicity matters here as well. Genomic reference databases have historically been built predominantly from people of European ancestry. This is a global problem, not unique to the UK, but it means that variant interpretation is genuinely less accurate for patients from South Asian, Black African or other non-European backgrounds. A genetic variant that looks unusual against a European reference population may be entirely normal in a Bangladeshi or Nigerian context, and vice versa. The NHS has made some effort to diversify its datasets, but the 100,000 Genomes Project cohort was roughly 78 per cent white British when analysed. Clinical decisions made from skewed data carry real risk for the patients those datasets underrepresent.
The data infrastructure problem nobody talks about
Whole genome sequencing generates enormous quantities of data. A single genome is around 200 gigabytes of raw reads. The NHS Genomic Medicine Service is sequencing tens of thousands of patients per year and that number is rising. Storing, linking, and meaningfully interrogating that data requires infrastructure that the NHS has not historically been designed to support.
NHS trusts still run a mixture of legacy electronic record systems. Getting genomic data to sit alongside clinical notes, pharmacy records and imaging in a way that a clinician can actually use during a consultation is technically and organisationally difficult. Interoperability between NHS systems is a longstanding problem, and genomics is merely the latest discipline to discover this the hard way. There are also legitimate data governance questions. The public’s trust in NHS data-sharing has been dented by past schemes, and the ICO’s oversight of health data remains a live policy issue, as I’ve written about elsewhere on this blog when covering how health app data privacy works under UK law. Patients are right to ask how their genomic data is stored, who can access it, and whether secondary research use requires their explicit consent.
The clinician training gap
Even where the infrastructure exists, many clinicians lack confidence with genomic results. Interpreting a variant of uncertain significance, explaining penetrance to a patient, or deciding whether a finding warrants cascade testing across a family are tasks that require specific training most doctors have not received. Medical schools are only beginning to embed genomics into undergraduate curricula in any meaningful way.
This matters because NHS genomic medicine cannot scale if it relies entirely on a small group of specialist clinical geneticists. The model that will actually work at population level is one where oncologists, cardiologists, neurologists and paediatricians all have enough genomic literacy to order, interpret and act on tests within their specialty. Building that workforce takes years. The government’s Genome UK strategy, published in 2020, acknowledged this gap and committed to addressing it. The pace of change in medical education, though, has been slow.
I find it useful to compare this with the self-diagnosis trap that many patients fall into while waiting for specialist input, which I’ve discussed in the context of NHS waiting lists and DIY health decisions. Genomics creates a version of the same pressure. Patients who can afford direct-to-consumer genetic tests from companies like Dante Labs or Genomics PLC are already getting partial information without clinical interpretation. That is not always safe, and it does not replace a conversation with a genetic counsellor.
What patients can actually expect right now
If you or your child has a rare undiagnosed condition, asking your GP for a referral to a clinical genetics service is the right first step. The GMS genuinely does deliver for this group, even if waiting times vary by region. For cancer, whether tumour profiling applies to your specific diagnosis depends heavily on cancer type and the capabilities of your treating trust. Haematological cancers and some solid tumours have well-established genomic pathways. Others do not yet.
For anyone hoping that mainstream preventive genomic medicine, knowing your polygenic risk scores for heart disease, diabetes or dementia before symptoms appear, is an NHS offering today, the honest answer is that it is not. Some pilot studies are running, including work through the NIHR and NHS England’s FH (familial hypercholesterolaemia) programme, but routine preventive genomics on the NHS remains years away for most people. The science is developing faster than the health system’s capacity to deploy it equitably.
NHS genomic medicine in the UK is genuinely world-leading in places. The ambition behind the GMS is sound. But ambition and delivery are different things, and the patients who most need genomic medicine, those with rare diseases, with harder-to-treat cancers, with family histories that warrant investigation, are often the same patients who face the longest waits, the least-informed clinicians, and the most uneven postcode lottery. Closing that gap requires honest assessment of where the system is actually falling short, not just more press releases about sequencing milestones.
Frequently Asked Questions
How do I get a genomic test on the NHS?
You need a referral from a specialist, typically through a clinical genetics service, an oncologist, or in some cases a paediatrician. GPs can refer you to clinical genetics if there is a relevant family history or suspected rare condition. Not all genomic tests are available through every NHS trust, so access depends partly on where you live and what condition is being investigated.
What conditions does the NHS Genomic Medicine Service cover?
The GMS focuses primarily on rare and inherited diseases and cancer genomics, including whole genome sequencing for patients with undiagnosed rare conditions and tumour profiling for certain cancers. It does not currently offer routine preventive or lifestyle genomic testing. The programme is expanding, but coverage varies by region and clinical indication.
Is NHS genomic data kept private?
Genomic data collected through NHS programmes is held under NHS data governance rules and subject to UK GDPR, overseen by the ICO. Genomics England operates under a specific data access framework where researchers must apply for access and agree to strict conditions. Patients can request information about how their data is used, and in most cases can opt out of secondary research use.